(Updated - February 23, 2024 9:23 AM EST)

Canaccord Genuity analyst Whitney Ijem raised the price target on Intellia ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Hot Comments

Evercore ISI Reiterates $70 PT on Intellia Therapeutics (NTLA), 'Year of P3 execution'February 23, 2024 9:27 AM Citi on Intellia Therapeutics (NTLA): 'we believe that NTLA-2001 might find its home as a niche offering'February 23, 2024 9:25 AM Goldman Sachs Downgrades Intellia Therapeutics (NTLA) to Neutral, 'A quieter 2024 catalyst path'February 23, 2024 9:19 AM Form S-8 Intellia Therapeutics, February 22, 2024 4:13 PM Form 10-K Intellia Therapeutics, For: Dec 31February 22, 2024 4:03 PM Form 8-K Intellia Therapeutics, For: Feb 22February 22, 2024 7:46 AM Intellia Therapeutics (NTLA) Misses Q4 EPS by 2cFebruary 22, 2024 7:37 AM Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressFebruary 22, 2024 7:30 AM